

Learner Notification

Total Health Conferences

Diversity in Cancer Care: Clinical Trials

February 1, 2022

Online

Acknowledgement of Financial Commercial Support

No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. You must attend the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health Conferences. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

Amedco LLC designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credits™* for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists

Amedco LLC designates this activity for a maximum of 1.0 knowledge-based CPE contact hours.

Nurses

Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hours.

Objectives - After Attending This Program You Should Be Able To

1. Review clinical applications in diagnostic and therapeutic approaches in cancer care, with an emphasis on the care of diverse populations
2. Discuss and debate challenges in design, treatment, and access to clinical trials for diverse and underrepresented populations
3. Discuss support systems approaches being designed to empower healthcare providers to reach and better treat at-risk populations

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5)

All individuals in a position to control the content of CE are listed in the program book. If their name is not listed below, they disclosed that they had no financial relationships with a commercial interest.

Name	Commercial Interest:Relationship
Tanya Dorff	Bayer, Exelixis, Abbvie, Astra Zeneca, Pfizer, SeaGen:Scientific/Medical Advisory Board Member
ARTURO LOAIZA-BONILLA	Amgen, AstraZeneca, Ipsen, Guardant, Natera:Speakers Bureau Massive Bio:Corporate Board Member Fresenius Kabi, Pfizer:Scientific/Medical Advisory Board Member
Jason Porter	Bristol Myers Squibb:Speakers Bureau Bristol Myers Squibb, Novartis, Jazz Pharmaceuticals, Astra Zeneca:Scientific/Medical Advisory Board Member
Gregory Vidal	NA

How to Get Your Certificate

1. Click on the **Diversity in Cancer Care: Clinical Trials** link.
2. Evaluate the meeting.
3. Print, download, or save your certificate for your records.